Advertisement
U.S. markets open in 4 hours 31 minutes
  • S&P Futures

    5,215.50
    +0.75 (+0.01%)
     
  • Dow Futures

    39,234.00
    +11.00 (+0.03%)
     
  • Nasdaq Futures

    18,232.00
    +0.50 (+0.00%)
     
  • Russell 2000 Futures

    2,047.10
    -2.70 (-0.13%)
     
  • Crude Oil

    82.53
    -0.19 (-0.23%)
     
  • Gold

    2,154.20
    -10.10 (-0.47%)
     
  • Silver

    25.07
    -0.20 (-0.79%)
     
  • EUR/USD

    1.0850
    -0.0027 (-0.25%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.42
    +0.09 (+0.63%)
     
  • GBP/USD

    1.2689
    -0.0039 (-0.31%)
     
  • USD/JPY

    150.3620
    +1.2640 (+0.85%)
     
  • Bitcoin USD

    63,185.67
    -4,824.21 (-7.09%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,723.62
    +1.07 (+0.01%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Aethlon Medical Third Quarter 2023 Earnings: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Aethlon Medical (NASDAQ:AEMD) Third Quarter 2023 Results

Key Financial Results

  • Net loss: US$2.85m (loss widened by 13% from 3Q 2022).

  • US$0.12 loss per share.

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aethlon Medical Earnings Insights

Looking ahead, revenue is expected to decline by 93% p.a. on average during the next 3 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.6%.

Performance of the American Medical Equipment industry.

The company's shares are up 4.8% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 5 warning signs for Aethlon Medical (3 can't be ignored!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Advertisement